Myricetin is a flavonol that exhibits anticancer, anti-metastatic, anti-hyperlipidemic, anti-fibrotic, neuroprotective, antioxidative, anti-diabetic, neuromodulatory, anti-osteoporotic, immunomodulatory, and chemopreventive activities. Myricetin inhibits proliferation and migration and induces cell cycle arrest in oral squamous cell carcinoma cells. In diabetic rats, myricetin decreases levels of total cholesterol, triglycerides, free fatty acids, LDL, and VLDL, increases levels of HDL, and suppresses the development of fibrosis. In cellular models of Alzheimer’s disease, myricetin scavenges radicals and inhibits amyloid-β (Aβ)-induced neurodegeneration. In other cellular models, myricetin enhances natural killer cell cytotoxicity. In vitro, this compound activates Wnt/β-catenin signaling, increasing osteoclast differentiation. This compound also improves insulin signaling and decreases glucose levels of diabetic rats. In vitro, myricetin inhibits catechol-O-methyl transferase (COMT).